The global obesity epidemic is fueling alarming rates of diabetes, associated with increased risk of cardiovascular disease and cancer. Leptin is a hormone secreted by adipose tissue that is a key regulator of body weight (BW) and energy expenditure. Leptin-deficient humans and mice are obese, diabetic, and infertile and have hepatic steatosis. Although leptin replacement therapy can alleviate the pathologies seen in leptin-deficient patients and mouse models, treatment is costly and requires daily injections. Because adipocytes are the source of leptin secretion, we investigated whether mouse embryonic fibroblasts (MEFs), capable of forming adipocytes, could be injected into ob/ob mice and prevent the metabolic phenotype seen in these leptin-deficient mice. We performed a single subcutaneous injection of MEFs into leptin-deficient ob/ob mice. The MEF injection formed a single fat pad that is histologically similar to white adipose tissue. The ob/ob mice receiving MEFs (obRs) had significantly lower BW compared with nontreated ob/ob mice, primarily because of decreased adipose tissue mass. Additionally, obR mice had significantly less liver steatosis and greater glucose tolerance and insulin sensitivity. obR mice also manifested lower food intake and greater energy expenditure than ob/ob mice, providing a mechanism underlying their metabolic improvement. Furthermore, obRs have sustained metabolic protection and restoration of fertility. Collectively, our studies show the importance of functional adipocytes in preventing metabolic abnormalities seen in leptin deficiency and point to the possibility of cell-based therapies for the treatment of leptin-deficient states. (Endocrinology 159: 3275-3286, 2018) M etabolic syndrome is a global epidemic that consists of multiple risk factors including central obesity and insulin resistance. Approximately 35% of adults in the United States meet the criteria for metabolic syndrome, which is associated with an elevated risk of developing type 2 diabetes and cardiovascular disease (CVD) (1, 2). CVD is the leading cause of death in the United States, and the combined annual cost associated with diabetes and CVD is .$500 billion (2). A contributing factor to the obesity epidemic is the recent large rises in energy intake, coupled with an increasingly sedentary lifestyle (3, 4). Numerous contributing factors play a role in body composition, yet hormones facilitate many processes regulating energy balance. A key hormone involved in the regulation of energy balance is leptin.
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Leptin is a principal component in the determination of adiposity. One of the main functions of leptin is to communicate the body's nutritional status to centers of the brain, primarily through the hypothalamus, to regulate many processes that control food consumption and energy expenditure (5) . Evidence indicates that multiple tissues are capable of leptin expression, but the predominant source of leptin is adipose (5) (6) (7) (8) (9) . Leptin levels are positively correlated with body mass index and percentage body fat in patients and are highly associated with total body triglyceride (TG) storage (10) (11) (12) . The amount of leptin closely reflects the body's nutritional status, and a deficiency can have profound metabolic consequences. Human leptin deficiency, caused by a mutation in the leptin gene, presents with hyperphagia, early-onset obesity, and hyperinsulinemia (13) (14) (15) . Leptindeficient ob/ob mice are a well-described model for metabolic studies that display hyperphagia and early-onset obesity (16) . Originally described in 1949, ob/ob mice have a mutation in the leptin gene (Lep) resulting in the production of a nonfunctioning protein and are a valuable tool for the study of metabolic defects and therapies for leptin deficiency (5, 16) . Furthermore, ob/ob mice have increased fatty acid synthesis in both adipose and liver in the setting of increased adiposity and hepatic steatosis (17) . Additionally, ob/ob mice have impaired glucose tolerance and insulin sensitivity, along with elevated levels of other hormones associated with insulin resistance, including insulin and gastric inhibitory polypeptide (GIP) (18) (19) (20) . Importantly, leptin-deficient humans and leptin-deficient ob/ob mice have been successfully treated with recombinant leptin to circumvent hyperphagia, obesity, and infertility (15, 21, 22) . Unfortunately, exogenous leptin therapy is expensive, has side effects, and can require multiple daily injections. It has been postulated that an ideal therapy would provide leptin endogenously (23) (24) (25) .
The production of endogenous leptin occurs primarily in white adipose tissue (WAT) (5) . Previous studies have shown that adipose from wild-type (WT) mice can be surgically implanted into ob/ob mice to circumvent metabolic consequences, but this method required multiple adipose donor mice and several adipose implants (26) . Recent work has shown that 3T3-L1 adipocytes overexpressing leptin can be encapsulated and injected into ob/ob mice (27) . Although ob/ob mice receiving overexpressing adipocytes did have an improvement in energy expenditure and glucose tolerance, there was no significant change in body weight (BW), fat mass, or insulin sensitivity (27) . Previous work has shown that 3T3-F442A preadipocytes can form fat pads similar to an epididymal WAT that is able to produce leptin in vivo. However, these fat pads expressed only 10% to 15% of leptin mRNA when compared with epididymal WAT. These studies were performed in immunodeficient athymic nude mice that produce leptin, and it was not possible to verify leptin secretion by these ectopic fat pads (28) . We and others have used mouse embryonic fibroblasts (MEFs) to generate adipocytes in vitro. These MEFs must be treated with an adipogenic cocktail consisting of the glucocorticoid dexamethasone, insulin, and 1-methyl-3-isobutylxanthine (a phosphodiesterase inhibitor that raises cAMP levels). As an alternative, we investigated whether a single injection of MEFs, which are capable of forming adipocytes, could improve the pathological metabolic phenotypes seen in leptin-deficient ob/ob mice in vivo.
Materials and Methods

Animals
Mice were purchased from Jackson Laboratories (B6.CgLep ob /J) as either homozygous (ob/ob) or heterozygous (ob/+) for use in studies or breeding, respectively. For prevention experiments, injection of WT C57Bl/6J MEFs was performed in male ob/ob mice at 2 to 3 weeks of age. Initial studies characterized mice 8 to 10 weeks after MEF injection, and long-term studies were performed in a separate cohort~7 months after MEF injections. For the final rescue experiment, injection of MEFs was performed in male ob/ob mice at 12 weeks of age and characterized 8 weeks after MEF injection. Animals were maintained on a 12-hour light, 12-hour dark cycle, in a temperaturecontrolled room (~22°C). All mice and procedures were on a protocol approved by the Institutional Animal Care and Use Committee of Washington University in St. Louis. Animals were given appropriate care while undergoing research that complies with the standards in the Guide for the Care and Use of Laboratory Animals (29) .
MEF isolation and injection
MEFs were prepared from E14 C57BL/6J mouse embryos and delivered via subcutaneous injection, as previously described (30, 31) . Briefly, mouse embryos were carefully collected after cervical dislocation in females on embryonic day 14. The embryonic head and internal organs were removed, and the remaining embryo was minced then added to a tube containing 1.25 mL of 0.05% trypsin/EDTA and incubated in a water bath for 45 minutes at 37°C. Next, 5 mL DMEM with 10% fetal bovine serum was added and pipetted vigorously 25 to 30 times, then passed through a 70-mm nylon mesh cell strainer into a new tube. The cell suspension was then centrifuged at 1000 rpm for 5 minutes and suspended in 150 mL PBS. The equivalent of MEFs from one embryo was injected into each mouse with a 25-gauge needle. MEFs were delivered by subcutaneous injection into the tissue overlying the sternum in mice under isoflurane anesthetization. Our group has previously shown that WT MEF-derived fat pads have similar expression of adipocyte-specific genes when compared with WAT (31).
Body composition
Composition of total body adiposity and lean mass were performed with EchoMRI-100H (EchoMRI LLC), as previously described (32) .
Histology
Hematoxylin and eosin (H&E) staining was performed on tissues fixed in 10% neutral buffered formalin. Slides were imaged with NanoZoomer (Hamamatsu NanoZoomer HT model) at 320 magnification. Adipocyte size was measured and calculated in Adiposoft software (ImageJ) (33) .
Liver TGs
Liver TGs were extracted and measured via the Folch method, as previously described (34, 35) . Briefly,~50 to 80 mg of liver was minced, weighed, and then extracted overnight in 2:1 chloroform/methanol. After phase separation, an aliquot of the bottom phase was removed, followed by the addition of 1% Triton X-100 in chloroform. The solvent was evaporated, then deionized water was added and TGs were quantified with Infinity™ Triglyceride Reagent (Thermo Scientific).
Glucose tolerance and insulin sensitivity
A glucose tolerance test (GTT) was performed in mice~8 to 10 weeks after MEF transplantation by fasting mice for 4 hours, followed by an IP injection of 10% dextrose: 2% volume/kg lean mass (as determined by EchoMRI) or 1% volume/kg BW, as indicated. Blood glucose was measured by tail bleed immediately before injection, and serial measurements were taken at 20, 40, 60, and 120 minutes after injection with a glucometer (Contour ® , Bayer). The next week, an insulin tolerance test (ITT) was performed after a 4-hour fast and an IP injection of insulin (Humulin R): 1 U/kg lean mass (as determined by EchoMRI) or 1 U/kg BW, as indicated. Blood glucose was measured by tail bleed immediately before injection, and serial measurements were taken at 20, 40, 60, and 120 minutes after injection. Glucose measurements were performed with a blood glucose monitoring system (Contour ® , Bayer).
Metabolic parameters
Indirect calorimetry and movement were determined with the TSE Systems Phenomaster automated metabolic caging system. Food and water intake was measured daily, for 1 week, in individually housed mice.
Plasma assays
Plasma analyses were performed commercially with a mouse metabolic array routine discovery assay (Eve Technologies).
Statistical analysis
Graphs were plotted in GraphPad Prism 7.0e (GraphPad Software, La Jolla, CA), and data are expressed as mean 6 SD. Data were analyzed with either a one-way or two-way ANOVA followed by post hoc analysis unless otherwise indicated. P , 0.05 was considered significant. A rescue index for ob/ob mice receiving MEFs (obRs) was quantified for several metabolic parameters as (ob/ob -obR)/(ob/ob -WT).
Results
Transplantation of MEFs prevents obesity and hepatic steatosis
To investigate whether the pathological metabolic phenotypes seen in leptin-deficient ob/ob mice could be prevented by a MEF-derived fat pad, we performed a single subcutaneous injection of MEFs, isolated from WT C57Bl/6J mice, overlying the sternum of 2-to 3-week-old male ob/ob mice. After 10 weeks, we found that ob/ob mice rescued with MEF implantation (obR) had a measurable amount of plasma leptin, yet it was only~6% of that found in WT mice [ Fig. 1(a) ]. Despite low levels of plasma leptin, obR mice had a 40% lower BW than ob/ob mice, as evidenced predominantly by a decrease in fat mass of 72%, with no difference in lean mass between groups [ Fig. 1(b) ]. This is equivalent to a rescue of 84% with regard to fat mass. To more closely examine WAT, we performed H&E staining on sections of epididymal WAT and MEF-derived fat pads [ Fig. 2(a) ]. Importantly, vascularization was observed in all groups, including in the MEF-derived fat pad [ Fig. 2(a) ]. Quantification of adipocyte area from H&E sections revealed that obR mice had a 42% smaller adipocyte area compared with ob/ob adipocytes; however, obR adipocytes were still 49% greater compared with WT adipocytes [ Fig. 2(b) ]. This represents a 69% rescue of the ob/ob phenotype. Notably, adipocytes from the ectopic MEF fat pad in obR mice were statistically similar in size to epididymal WAT of WT mice [ Fig Because transplantation of MEFs clearly reduced obesity due to leptin deficiency, we next investigated the effect of MEFs on hepatic steatosis in leptin deficiency. First, we saw that obR mice had a dramatic 57% lower liver weight [ Fig. 3(a) ] and 25% lower liver/BW ratio when compared with ob/ob mice [ Fig. 3(b) ], representing rescues of 85% and 81%, respectively. Next, liver TGs were determined biochemically, and we saw that ob/ob mice had~12-fold higher liver TGs compared with obR liver TGs, which were similar to those of WT mice [ Fig.  3(c) ] and resulted in a rescue of 97% of the ob/ob Glucose tolerance and insulin sensitivity restored by MEF transplantation Next, we examined the effect of MEF transplantation on glucose tolerance and insulin sensitivity in leptindeficient mice. We found that obR mice had fasting plasma levels of insulin 76% lower than those of ob/ob mice [ Fig. 4(a) ], which matches a rescue value of 82%. In addition, we saw improvements in other hormones associated with insulin resistance and obesity, including amylin, C-peptide, and GIP, and a trend toward decreased resistin [ Fig. 4 (b)-4(h)]. A GTT was performed and revealed that obR mice had better glucose handling than leptin-deficient mice, with a 32% reduction in area under the curve (AUC) [Fig. 4(i) ], consistent with a 100% rescue. Furthermore, obR mice had greater insulin sensitivity than ob/ob mice, as evidenced by ITT, where obR mice had a substantially lower AUC than ob/ob mice [ Fig. 4(j) ], with a rescue value of 62%. Importantly, obR mice had similar values to WT mice at all time points for the GTT and ITT, and similar AUC values.
Increased energy expenditure and decreased food intake in obR mice
To explore mechanisms that could explain the improvements in metabolic endpoints in obR mice, we placed mice in metabolic chambers. Oxygen consumption was increased by 75% to 77% (as the mean of light and dark cycle measurements) in obR relative to ob/ob mice [ Fig. 5(a) ], which correspond to rescues of 74% and 81%, respectively. There was no change in the source of energy burned (i.e., carbohydrate vs fat), as evidenced by a similar respiratory exchange ratio between all groups [ Fig. 5(b) ]. As expected, obR mice had greater energy expenditure than ob/ob mice, with a 76% to 80% rise during light and dark cycles [ Fig. 5(c) ], which reflects rescues of 73% and 81%, respectively. Lastly, obR mice movement was 2.7 and 3.2 times higher than that of ob/ ob mice in the light and dark cycle, consistent with rescues of 67% and 83%, respectively [ Fig. 5(d) ]. In addition, obR mice had a 26% lower food intake [ Fig. 6(a) ] and 27% lower water intake [ Fig. 6(b) ] in obR compared with ob/ob mice, corresponding to a 66% and 87% rescue, respectively.
MEF transplantation prevents metabolic defects in ob/ob mice in the long term Next, to determine whether MEF transplantation could sustain protection in leptin-deficient mice, we Significance determined by one-way ANOVA. *P , 0.05; **P , 0.01; ***P , 0.001; ****P , 0.0001. characterized mice~7 months after MEF transplantation rather than after only 10 weeks, as performed in the first cohort. Again, we observed that obR mice had a measurable amount of plasma leptin, yet this was only~13% of that found in ob/+ mice [ Fig. 7(a) ]. obR mice had substantially lower BW than ob/ob mice, chiefly because of a 72% decrease in adipose tissue mass, corresponding to a rescue of 98%, with no difference in lean mass [ Fig.  7(b) ]. MEF fat pads (0.79 6 0.21 g) made up 2.2% of obR BW. Furthermore, liver weight was 65% lower in obR mice than in ob/ob mice, equivalent to a rescue of 93% [ Fig. 7(c) ]. Although hyperglycemia is largely absent in ob/ob mice of this age, we did observe a decrease in plasma insulin by 98% in obR relative to ob/ob [ Fig. 7(d) ]. Lastly, MEF transplantation into leptin-deficient ob/ob mice also restored fertility. Four male obR mice, at 3 to 4 months of age, were bred with WT females, resulting in litters within 1 month in all four cages. In addition, 3-to 4-month-old obR females produced litters when bred with WT male mice within a month of breeding.
Rescue of obese mice with MEF injection
Because our previous experiments demonstrated that MEF implants prevent the onset of obesity and other metabolic consequences associated with leptin deficiency in ob/ob mice, we next investigated whether the injection of MEFs could rescue ob/ob mice that were already morbidly obese. We injected MEFs into 12-week-old ob/ ob mice that were obese and hyperglycemic. Both ob/ob and obR mice continued to gain BW in the first 2 weeks, yet the BW in obR mice peaked at 2 weeks, then declined, reaching statistical significance 4 weeks after MEF implantation [ Fig. 8(a) ]. After a total of 8 weeks after MEFs, obR mice had a 30% lower BW than ob/ob mice [ Fig.  8(a) ]. Additionally, fat mass in obR mice was decreased by 2.3-fold relative to ob/ob mice, and there was no significant difference in lean mass [ Fig. 8(b) ]. MEF fat pads (1.0 6 0.07 g) made up~2.4% of obR BW. As with our previous experiments, we found that obR liver weight was 46% less than that in ob/ob mice [ Fig. 8(c) ]. Glucose tolerance was also improved in obR mice, with an 2.5-fold lower AUC compared with ob/ob mice [ Fig.  8(d) ]. Lastly, insulin sensitivity was also improved in obR mice, as evidenced by an ITT AUC that was much lower than that of ob/ob mice [ Fig. 8(e) ].
Discussion
Leptin is produced by WAT and plays a critical role in the regulation of nutritional status, body composition, metabolism, and reproduction. Leptin deficiency manifests itself as severe obesity, hepatic steatosis, and insulin resistance in humans and rodent models. This condition can be successfully treated with the use of recombinant leptin injections (15, 23) . In this work, we aimed to determine whether leptin production by WT MEF-derived fat pads is capable of preventing and rescuing the metabolic derangements observed in leptin-deficient ob/ob mice. Our results confirm that MEFs injected subcutaneously into ob/ob mice develop into fat pads that are histologically similar to epididymal WAT and are capable of producing measurable amounts of leptin in the plasma. Importantly, before the onset of obesity, obR mice were protected from fat mass accumulation and hepatic steatosis. These results correlated with increased energy expenditure and decreased food intake as well as . Significance determined by either two-way (GTT and ITT) or one-way ANOVA. *P , 0.05; **P , 0.01; ***P , 0.001; ****P , 0.0001. substantial improvement in glucose tolerance and insulin sensitivity. The protection from obesity was sustained in the long term, as phenotyping in a separate cohort of mice at 7 months yielded similar results. In our final assessment, we determined that obese ob/ob mice injected with MEFs later in life (at 12 weeks of age) demonstrated loss of fat mass, as well as a resolution of hepatic steatosis and improvements in glucose homeostasis. Our study demonstrates a role of in vivo development of WT MEFderived fat pads in preventing and rescuing the development and progression of long-term metabolic disease in the leptin-deficient ob/ob mouse model.
A plausible explanation for the effects seen in obR mice is that WT MEF-derived fat pads resulted in sufficient production of functional leptin to compensate for the lack of leptin in the ob/ob mouse, thereby ameliorating the metabolic derangements observed in the model. Although one could argue that other adipokines produced by the fat pad could be contributing to the improvement in metabolic parameters, this possibility seems less likely because ob/ob mice are only deficient in leptin and retain their sensitivity to leptin signaling. The possibility of leptin as a driving factor in obR protection is further substantiated by past studies in lipodystrophic mice. Lipodystrophy, a condition characterized by the degenerative loss of adipose tissue, leads to severely low leptin levels and development of insulin resistance and hepatic steatosis; however, it can be effectively treated with leptin replacement therapies (36, 37) . Earlier work in a mouse model of lipodystrophy showed that transplantation of WAT from WT mice remedies metabolic complications in lipodystrophic mice (38) . Conversely, adipose transplanted from leptin-deficient ob/ob mice has no effect (39) . Remarkably, leptin levels observed in our obR mice were only 5% to 15% of baseline levels seen in control mice. Previous studies have shown that plasma leptin as low as 0.5 ng/mL (relative to background) is associated with decreased BW and increased satiety (40) , which is similar to what we observed in our studies. Unexpectedly, younger WT mice had leptin levels approximately six times higher [ Fig. 1(a) ] than those of 7-month-old ob/+ mice [ Fig.  7(a) ]. Although we cannot fully explain the variation, it could be caused by heterozygosity for the leptin allele. Previous evidence has suggested that ob/+ mice produce less leptin protein per mass of body fat than normal +/+ mice (41) .
Our studies suggest that leptin is acting in obR mice by promoting satiety and stimulating increased energy expenditure. Leptin achieves these actions primarily at the level of the central nervous system and is a key regulator in food intake in humans and mouse models (42, 43) . Evidence has shown that decreased food intake is only partially responsible for the effects of leptin therapy in improving ob/ob mice, and increased energy expenditure in obR mice probably plays a large role as leptin administration leads to activation of sympathetic input and increased catecholamine production (44) (45) . Although satiety and increased energy expenditure are important driving factors in restoring metabolic homeostasis in obR mice, we cannot exclude the effect of leptin in peripheral tissues, and additional studies are needed to determine the exact role this effect plays in improving metabolic regulation in obR mice. The leptin receptor is expressed . Significance determined by one-way ANOVA. **P , 0.01; ***P , 0.001; ****P , 0.0001. Figure 6 . Food intake decreased in rescue mice. Intake of (a) food and (b) water was measured daily for 1 week and averaged for each mouse. Data are expressed as group mean 6 SEM (n = 4 to 5). Significance determined by one-way ANOVA. *P , 0.05; **P , 0.01.
in multiple peripheral tissues, and leptin has been shown to have beneficial effects on glucose homeostasis (47) (48) (49) (50) . In adipocytes and WAT ex vivo, lipolysis is increased upon leptin administration, in addition to an increase of glucose utilization by brown adipose (51) . Studies have also shown that fatty acid oxidation is increased in skeletal muscle, and insulin sensitivity is improved in the liver (52, 53) . Furthermore, leptin has been found to decrease insulin transcription and secretion in pancreatic islet cells (54) (55) (56) .
In this report, we demonstrate a simple, effective, and sustainable method of resolving the phenotypic effects of leptin deficiency in the ob/ob mouse model. Leptin gene therapy via adenoviral transduction has been attempted in ob/ob mice, yet success was limited by low expression levels, rodent death after therapy, and lack of sustained improvement in phenotype (25, 57) . In our study, all mice treated with MEFs survived and were protected from obesity for up to 7 months. Additionally, compared with adenoviral leptin production, daily treatment with recombinant leptin achieved a far greater decrease in BW over time (25) , which showed a similar trend to what we observed in our obR mice 3 weeks after MEF implantation (Fig. 8) . Interestingly, weight loss occurred between 2 and 3 weeks after transplantation into adult ob/ob mice, and this weight loss coincided with in vitro differentiation of MEFs into adipocytes, which takes 2 weeks with an adipogenic cocktail (30) . Implantation of gut-derived cells, engineered with a mifepristone-inducible leptin expression construct, has also been used to help improve metabolic effects in ob/ob mice. Although these mice demonstrated a decrease in BW and food intake, the observed effect depended on mifepristone treatment, and animals regained fat mass and food intake after therapy cessation (58) . These interpretations are further complicated by the use of mifepristone, which is a glucocorticoid receptor antagonist, and glucocorticoid levels can be associated with the development of metabolic syndrome (59) . Another group attempted to rescue ob/ob mice with encapsulated, leptin-overexpressing 3T3-L1 cells. Although improvements were noted in glucose tolerance and insulin sensitivity, adipose tissue formation was not documented, and ob/ob mice were not protected from obesity or hyperphagia (27) . These findings are in contrast to our study and may be related to inefficient fat pad formation in the 3T3-L1 model.
Our work shows that leptin-deficient ob/ob mice provide an adequate host environment for MEF-derived fat pad development in vivo. Our findings differ from those of previous studies that used diet-induced obesity (DIO) models and showed that DIO mice were not suitable hosts for adipogenesis when injected with purified preadipocytes (60) . A likely explanation for this finding is that DIO mice tend to be leptin resistant, whereas ob/ob mice retain sensitivity to leptin signaling. It is also worth considering that ob/ob mice are hyperinsulinemic, providing another possible requirement for fat pad development. Hyperinsulinemia is also present in lipodystrophy, and several studies have shown that fat pads are capable of developing in these settings (31, 60, 61) . Insulin has been shown to play an important role in the development of adipocytes, and it is possible that high insulin levels are necessary for the development of fat pads in vivo in the setting of obesity. Although hyperinsulinemia is present in all the previously mentioned models, earlier evidence has shown that ob/ob and lipodystrophic mice have insulin levels that are many times greater than those of DIO mice (62-65). Additionally, ob/ob and lipodystrophic mice are Other groups have used a purified cell population subset isolated by flow cytometry based on the expression or lack of expression of certain cell surface markers (60, 69, 70) . In contrast, our study used unpurified fibroblasts from E14 mouse embryos, which sufficiently formed WAT in vivo. Alternatively, adipose tissue transplants have also been used to counteract the phenotype of ob/ob mice. Ashwell et al. (71) successfully transplanted fat tissue from C57BL/6 into ob/ob mice; however, the metabolic effects of the fat transplants in obese mice were not examined. Work in lipodystrophic mice has revealed that the amount of fat transplanted is proportional to the amount of leptin secretion (38) . Later studies found that transplantation of WAT from C57BL/6 mice into ob/ob mice resulted in increased plasma leptin and reductions in BW, food intake, and hyperinsulinemia. Unfortunately, this effect required transplants from four to eight donors, requiring #30 injections (26) . Notably, WT MEF-derived fat pads were the result of a single injection, and fat pad mass was~0.5 to 1 g in size, which was sufficient for ameliorating effects on BW and was sustained over time.
Finally, it is important to mention the practical implications of our work in relation to the restoration of fertility in ob/ob mice. Under normal circumstances, obtaining sufficient ob/ob homozygous progeny is expensive and timeconsuming because successful breeding occurs only with heterozygous animals. Treatment with recombinant leptin is sufficient to restore fertility in ob/ob mice, yet this requires daily injections (72) . Recent reports indicate that adipose transplants effectively restore fertility in ob/ob mice and improve the generation of homozygous offspring, but this procedure requires skilled survival surgery and up to eight transplantations (73) . In contrast, our method successfully restores fertility to ob/ob mice after a single injection of MEFs in mice under light sedation. Furthermore, a single pregnant dam can provide embryos for MEFs to sufficiently rescue up to eight ob/ob mice.
Collectively, our studies show that fat pads derived from WT MEFs can ameliorate the negative effects on wholebody energy homeostasis and infertility in leptin-deficient ob/ob mice. Importantly, MEF-derived fat pads are capable of sustaining benefits in the long term and may be applied to other types of leptin deficiency, including lipodystrophy. Future studies may provide a better understanding of in vivo fat development and aid in the discovery of treatments for metabolic diseases. Our findings suggest the possibility of future cell-based therapies for patients with leptin deficiency, lipodystrophy, or other mutations in adipose-specific genes.
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